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Background: Dysregulations in cholesterol and lipid metabolism have been linked to human diseases like
hypercholesterolemia, atherosclerosis or the metabolic syndrome. Many ABC transporters are involved in trafficking
of metabolites derived from these pathways. Pseudoxanthoma elasticum (PXE), an autosomal-recessive disease
caused by ABCC6 mutations, is characterized by atherogenesis and soft tissue calcification.
Methods: In this study we investigated the regulation of cholesterol biosynthesis in human dermal fibroblasts from
PXE patients and healthy controls.
Results: Gene expression analysis of 84 targets indicated dysregulations in cholesterol metabolism in PXE
fibroblasts. Transcript levels of ABCC6 were strongly increased in lipoprotein-deficient serum (LPDS) and under
serum starvation in healthy controls. For the first time, increased HMG CoA reductase activities were found in PXE
fibroblasts. We further observed strongly elevated transcript and protein levels for the proprotein convertase
subtilisin/kexin type 9 (PCSK9), as well as a significant reduction in APOE mRNA expression in PXE.
Conclusion: Increased cholesterol biosynthesis, elevated PCSK9 levels and reduced APOE mRNA expression newly
found in PXE fibroblasts could enforce atherogenesis and cardiovascular risk in PXE patients. Moreover, the increase
in ABCC6 expression accompanied by the induction of cholesterol biosynthesis supposes a functional role for
ABCC6 in human lipoprotein and cholesterol homeostasis.
Keywords: Pseudoxanthoma elasticum, ABC transporter, ABCC6, Cholesterol biosynthesis, Atherosclerosis, HMG CoA
reductase, SREBP2, PCSK9, LDLR, APOEBackground
ATP Binding Cassette (ABC) proteins are important
transporters for the delivery of hydrophobic compounds
across cellular membranes [1]. To date, 48 human trans-
porters have been described which can be classified into
7 subgroups [2]. Many ABC transporters are involved in
trafficking of metabolites derived from lipid or choles-
terol biosynthesis, e.g. sterols, bile acids, phospholipids,
or sphingolipids [3]. Moreover, genetic mutations in
ABC transporters have been linked to various human
diseases [2,3], like Dubin–Johnson syndrome (ABCC2),
Tangier disease (ABCA1), or Pseudoxanthoma elasticum
(ABCC6).* Correspondence: dhendig@hdz-nrw.de
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unless otherwise stated.In contrast to other human transmembrane trans-
porters, the characteristics and substrate spectra of which
have already been explored, the function and physiological
role of ABCC6 is still unclear [4]. Pseudoxanthoma elas-
ticum (PXE) is an autosomal recessive disorder with an
estimated prevalence of 1: 25.000- 50.000 [5]. To date,
up to 350 causative genetic mutations have been found
in ABCC6 [6].
PXE is characterized by soft tissue calcification affecting
the skin, eyes and cardiovascular system [7]. Morpho-
logically, mineralization occurs on elastic fibers which
show increased degradation in PXE patients, in addition
to abnormalities in collagen fibril assembly [8] and accu-
mulation of proteoglycans [9]. Patients suffer from prema-
ture atherosclerosis, reduction in skin elasticity and visual
detractions (angioid streaks, peau d’orange) [10]. Yellowish
papules, marking flexural body sites, appear during thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acterized by cholesterolester accumulations in dermal
foam cells [12], where cutaneous lesions of PXE derived
from elastin calcification and fragmented fiber deposits
[13]. The involvement of cholesterol or lipid depositions
in PXE papule development is not clear. However, lipo-
proteins like the low density lipoprotein (LDL) have
been examined for their capacity to bind to elastin, which
increases under atherosclerotic conditions [14,15].
ABCC6 is primarily expressed in the human liver and
kidney, and to a lesser extent has been found in the skin,
neural retina and vessel walls [16]. Moreover, Beck et al.
detected ABCC6 mRNA in murine intestine, colon,
brain, and eye [17]. Human dermal fibroblasts served as
an appropriate model for soft tissue calcification in recent
studies [7,18,19]. In addition to human skin fibroblasts,
Abcc6-deficient (Abcc6 −/−) mouse models were estab-
lished for the examination of PXE pathogenesis [20,21].
Regarding the functionality and physiological role of
ABCC6, essential knowledge is still missing. Several stud-
ies have been carried out to elucidate substrate specifica-
tions of ABCC6 in vitro, demonstrating the transport of
glutathione conjugates [10]. However, in vitro experiments
and investigations of Abcc6 in mice showed no transport
activity for vitamin K3-glutathione conjugates or adeno-
sine [22,23], rejecting previous ideas for its potential
functionality [24,25].
About twenty ABC transporters are involved in the
carriage of compounds derived from lipid- or cholesterol
metabolism and are important for reverse cholesterol
transport (RCT) and phospholipid- and cholesterol efflux
[3,26]. Voloshyna and Reiss summarized the functional
role of ABCA1, ABCG1, ABCG4, ABCA5 and ABCA7
transporters in high-density lipoprotein (HDL)-mediated
RCT, as well as ABCG5, ABCG8, ABCB4 and ABCB11
for biliary lipid secretion within the scope of atheroprotec-
tion [26]. Additionally, members of the ABCC subgroup,
like ABCC1, ABCC2 and ABCC3, are further needed for
bile acid and bilirubin efflux [3]. Studies have described
genetic mutations in ABCC6 to be associated with varia-
tions in quantitative plasma lipoproteins [27], low HDL-C
and/or coronary heart disease (CHD) risk [28]. Alterations
in lipoprotein composition with lowered plasma HDL
cholesterol levels and hypertriglyceridemia were found in
plasma samples of PXE patients [29]. Furthermore, experi-
ments in Abcc6 −/− mice showed a 25% reduction in
plasma HDL cholesterol [20], confirming the potential
role of ABCC6 in lipid homeostasis as described before
[30]. Recently, Guo et al. demonstrated that atorvastatin
counteracts soft tissue mineralization in Abcc6-deficient
mice [31]. Statins are widely used to inhibit HMG CoA
reductase activity, the rate-limiting step in cholesterol
biosynthesis, to reduce plasma low-density lipoprotein
cholesterol (LDL-C) levels and CHD risk [32]. Oxidized-LDL fractions have been described as the major stimuli
for plaque formation and atherosclerotic development
[33], as well as for angiogenesis [34]. In addition to sta-
tin treatments, inhibition of the proprotein convertase
subtilisin/kexin type 9 (PCSK9) is under recent examin-
ation to lower circulating LDL levels, while PCSK9 nega-
tively regulates the low-density lipoprotein receptor (LDLR)
by promoting its lysosomal degradation [35].
Here, we describe for the first time HMG CoA reduc-
tase activity measurements in human dermal fibroblasts
derived from PXE patients and healthy controls, as well
as for ABCC6-silenced cells. Moreover, we carried out
gene expression profiling of 84 targets involved in chol-
esterol biosynthesis and lipoprotein signaling in human
dermal fibroblasts cultivated without fetal calf serum
(−FCS) for 24 h. Significant alterations were further in-
vestigated under different cell culture conditions, using
10% fetal calf serum, 10% lipoprotein-deficient serum
(LPDS) and serum starvation (−FCS) to stimulate HMG
CoA reductase activity. Our results indicate that func-
tional loss or dysfunction of ABCC6 in PXE dermal fibro-
blasts is significantly associated with alterations in cellular
cholesterol metabolism and lipoprotein assembly.
Materials and methods
Cell culture
Primary human dermal fibroblasts from four PXE patients
were isolated and specified as described previously [18].
None of the investigated patients was reported to suffer
from dyslipidemia. Dermal fibroblasts from four appar-
ently healthy controls were purchased from Promocell
(Heidelberg, Germany), Genlantis (San Diego, USA),
Cambrex (Walkersville, USA) and Coriell Institute for
Medical Research (Camden, USA). All cells were iso-
lated and characterized by standard methods. The study
was approved by the ethics commission of the Ruhr
University of Bochum Faculty of Medicine, located in Bad
Oeynhausen. All patients provided their written informed
consent to participate in the study. Characterization of
human dermal fibroblasts is given in Additional file 1:
Table S1. Cultivation was performed in Dulbecco’s modi-
fied essential medium (DMEM, Gibco) containing 10%
fetal calf serum (PAN Biotech, Aidenbach, Germany),
1% L-glutamine (200 mM) and 1% antibiotic/antimycotic
solution without phenol red, whereupon cells were subcul-
tured every 4–5 days (1:3) as they reached confluence.
For experiments cells were grown for 24 h in 10% FCS
(177 cells/mm2, BD Falcon), washed twice with phosphate-
buffered saline (PBS; Gibco), and replaced with either
10% fetal calf serum (FCS), lipoprotein-deficient FCS
(LPDS) [36], or without serum for additional 24 h. Cells
reached approx. 70- 80% of confluence after stated time
of growth. Biological samples were prepared in tripli-
cates using passages 7–10. Cells harvested for RNA
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before [37,38].Gene silencing of ABCC6 using small-interfering RNA
Lipofectamine 2000 reagent (Invitrogen- Life technologies,
Darmstadt, Germany) was used to deliver ABCC6-specific
small-interfering RNA (siRNA-ID 106395) and FAM
labeled scrambled control siRNA oligonucleotides (Ambion-
Life technologies, Darmstadt, Germany) to dermal fibro-
blasts of healthy controls during reverse transfection, in
a total siRNA-concentration of 40 nM. No antibiotic/
antimycotic solution was used during the first 12 h. Cell
culture medium was replaced with fresh media 12 h
post-transfection, whereupon transfection efficiencies
were examined by fluorescence microscopy of FAM la-
beled controls. Cells were cultivated for additional 48 h in
10% FCS, followed by 24 h cultivation in either 10% FCS,
10% lipoprotein deficient serum (LPDS), or without FCS.RT2 Profiler PCR Array
A broad gene expression analysis was performed cover-
ing 84 target genes involved in lipoprotein signaling and
cholesterol metabolism by using RT2 Profiler PCR Array
(Qiagen, Hilden, Germany, PAHS 080ZA). PCR array was
performed with cells cultivated for 24 h without FCS, and
3 biological replicates were pooled for array analysis. RNA
was isolated as described before [37], whereupon 400 ng
were used for cDNA-synthesis (RT2 First Strand Kit;
Qiagen, Hilden, Germany). Real-Time PCR was performed
using LightCycler® 480 (Roche, Penzberg, Germany) and
RT2 SYBR Green qPCR reaction mixture (Qiagen, Hilden,
Germany). Reaction mixture and PCR cycles were per-
formed according to the manufacturer’s instructions.
Relative gene expression was analyzed using ΔΔCt based
fold-change calculations.Real time quantitative PCR analysis
Real-Time quantitative PCR (qPCR) was performed
using LightCycler 480 and LightCycler 480 SYBR Green
I Master reaction mixture (Roche, Penzberg, Germany).
RNA was isolated as described above, whereupon 2 μg
were used for cDNA-synthesis (SuperScript II Reverse
Transcriptase, Invitrogen- Life technologies, Darmstadt,
Germany).
Primer sequences are listed in Additional file 2: Table S2.
cDNA was used at 1:10 dilution; targets with low gene
expression were measured using 1:5 diluted cDNA. A
cutoff for no detectable mRNA expression was set to a
Ct level of 35 for further relative gene expression ana-
lysis (carried out as described before [18]), with ACTB,
GAPDH and β2M as reference genes, according to
MIQE guidelines [39].Protein extraction and quantification
Preparation of protein lysates was performed as described
before [38]. Total protein content of cell lysates was es-
timated using bicinchoninic acid assay (BCA Kit, Sigma
Aldrich, Taufkirchen, Germany).
HMG CoA enzyme activity assay
Enzyme activity assay for HMG CoA reductase was de-
termined for each biological replicate. Procedures were
carried out as described before [38], using 100 μM of
HMG CoA as initial substrate. Detection of MVL levels
was monitored by an ultra-performance liquid chromatog-
raphy (UPLC) system (Waters Acquity UPLC) using a
2.1 mm× 150 mm HSS PFP UPLC/MS cartridge (Waters,
1.8 μm ACQUITY UPLC HSS PFP Column) conducted at
45°C, which was directly coupled to a Quattro LC tandem
mass spectrometer equipped with Z Spray ion source
(Waters Xevo™ TQ-S).
Quantitation of cellular proprotein convertase subtilisin/
kexin type 9 (PCSK9)
Human PCSK9 in cell lysates of dermal fibroblasts was
measured using Human PCSK9 ELISA Kit (Cell Biolabs,
Inc., San Diego, USA) according to the manufacturer’s
instructions. Protein lysates were obtained as described
above. 5 μg of total cellular protein were used for enzyme
immunoassay, measuring fibroblast samples in duplicates.
Apolipoprotein E (APOE) genotyping
Genotyping of apolipoprotein E was performed according
to the previously published method by Wenham et al.
[40]. Isolated DNA of patients and controls was screened
for apolipoprotein E sequence variations at position c.334
(T > C) and c.472 (C > T) by PCR on a LightCycler 480
(Roche, Applied Science). PCR was performed with
fluorescence resonance energy transfer (FRET)-probes
(fluorescein, LCRed 640). APOE genotypes were identi-
fied using melting curve analysis. Specific melting peak
detection allows the characterization of homozygous or
heterozygous sequence types, regarding melting tem-
peratures and number of peaks.
Statistical analysis
Experimental data are indicated as means ± S.E. Graphic
data processing and statistics were performed with
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla,
USA) using Mann-Whitney U Test (significance level
p < 0.05).
Results
RT2 profiler PCR array
Analysis of 84 genes involved in cholesterol metabolism
and lipoprotein signaling revealed altered mRNA levels
between PXE fibroblasts and healthy controls grown in
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expressions regulated > 2-fold, or < 0.5-fold between
PXE and control cells, as well as for siRNA-transfected
cells. All results of PCR profiler array are provided in
Additional file 3: Table S3. Fold-changes were character-
ized by comments (OKAY/A/B/C) based on the gene’s
average threshold cycle as described in Table 1. Relative
mRNA expression of proprotein convertase subtilisin/
kexin type 9 (PCSK9) exhibited a 46-fold increase in
PXE fibroblasts (p < 0.04) compared to healthy controls,
whereas no differences were found between siRNA-
transfected cells. Furthermore, 2.4-fold elevation of
transmembrane 7 superfamily member 2 (TM7SF2)
mRNA level in PXE cells revealed statistical significance
(p < 0.04), which was also confirmed by trend with




ABCG1 ATP-binding cassette, sub-family G member 1 1
ANGPTL3 Angiopoietin-like 3 3
APOD Apolipoprotein D 2
APOE Apolipoprotein E 0
APOF Apolipoprotein F 0
APOL1 Apolipoprotein L, 1 12
APOL5 Apolipoprotein L, 5 0
CEL Carboxyl ester lipase (bile salt-stimulated lipase) 2
CXCL16 Chemokine (C-X-C motif) ligand 16 0
CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide 1 3
CYP46A1 Cytochrome P450, family 46, subfamily A, polypeptide 1 0
HDLBP High density lipoprotein binding protein 6
LRP1B Low density lipoprotein receptor-related protein 1B 5
NPC1L1 NPC1 (Niemann-Pick disease, type C1, gene) like 1 0
OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 0
PCSK9 Proprotein convertase subtilisin/kexin type 9 4
SORL1 Sortilin-related receptor, L(DLR class) A repeats containing 1
TM7SF2 Transmembrane 7 superfamily member 2 2
TRERF1 Transcriptional regulating factor 1 4
Regulated gene expression of human dermal fibroblasts of PXE patients and health
without FCS for 24 h.
afold-Change (2^(−ΔΔCt)) is the normalized gene expression (2^(−ΔCt)) in the test s
control sample.
bp-values are calculated based on a Student’s t-test of the replicate 2^(−ΔCt) values
than 0.05 are printed in bold.
ccomments
OKAY: This gene's average threshold cycle is below 30 in the control and test samp
A: This gene’s average threshold cycle is relatively high (>30) in either the control o
B: This gene’s average threshold cycle is relatively high (>30), meaning that its relat
for the fold-change is either unavailable or relatively high (p > 0.05).
C: This gene’s average threshold cycle is either not determined or greater than the
was undetected, making this fold-change result erroneous and un-interpretable.other regulations were elevated or decreased by trend
and no statistical significance was found due to in-
sufficient sample size or low expression levels (see also
comment description, Table 1. Array analysis showed
distinct differences in apolipoprotein mRNA expres-
sions between patient and control samples. A 124.6-fold
increase was found for apolipoprotein L1 (APOL1) ex-
pression in PXE fibroblasts compared to control cells.
Although, transcript levels of apolipoprotein D (APOD)
were 2.3-fold higher in PXE fibroblasts. Expressions of
apolipoprotein E (APOE), F (APOF) and L5 (APOL5)
were decreased in PXE samples (patient/control ratio:
0.07; patient/control ratio: 0.5; patient/control ratio: 0.2,
respectively), whereas a reduction in APOE expression
was also confirmed by siRNA treatments (siABCC6/











.89 0.334 B 0.34 0.421 B
.09 0.249 A 1.24 0.294 A
.29 0.328 OKAY 0.92 0.796 OKAY
.07 0.313 A 0.51 0.847 A
.47 0.353 B 1.90 0.343 B
4.57 0.095 A 1.03 0.919 B
.23 0.123 B 1.05 0.660 C
.68 0.341 A 2.84 0.331 A
.49 0.192 B 1.09 0.869 OKAY
.64 0.068 A 1.05 0.809 B
.57 0.250 B 0.47 0.192 B
.99 0.751 OKAY 0.99 0.989 OKAY
.18 0.092 B 0.43 0.265 B
.36 0.161 B 0.89 0.562 B
.29 0.120 B 2.34 0.581 B
6.23 0.033 A 1.18 0.820 B
.77 0.112 B 2.18 0.390 B
.40 0.034 OKAY 2.05 0.079 OKAY
.93 0.222 OKAY 3.98 0.209 OKAY
y controls (PXE/controls) and siRNA transfected cells (siABCC6/siNK) cultivated
ample divided the normalized gene expression (2^(−ΔCt)) in the
for each gene in the control group and treatment groups, and p values less
les.
r the test sample, and is reasonably low in the other sample (<30).
ive expression level is low, in both control and test samples, and the p-value
defined cut-off value (default 35), in both samples meaning that its expression
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highly increased under serum starvation
As shown in Figure 1a, no mRNA expression of ABCC6
was quantifiable in PXE fibroblasts. Relative gene ex-
pression of ABCC6 was significantly increased in con-
trol fibroblasts under lipoprotein-deficient conditions
(1.9-fold) and serum starvation (7.1-fold). A similar ex-
pression pattern was observed in siRNA-transfected
control cells (Figure 1b; +10% LPDS: 1.6-fold; -FCS:
5.0-fold), while transcript levels of ABCC6 were down-
regulated by 64.5% (10% FCS), 65% (10% LDPS) and
75.2% (−FCS) in siABCC6-transfected cells compared
to siNK (p < 0.0001).
Elevated HMG CoA reductase (HMGCR) enzyme activity in
PXE fibroblasts
Determination of HMGCR gene expression by qPCR re-
vealed a significant increase in accordance with modified
cell culture conditions (Figure 2a) in PXE and control fi-
broblasts compared to fibroblasts cultivated in 10% FCS
(+10% LDPS: control, 2.6-fold; PXE, 2.9-fold; −FCS:
control, 1.4-fold; PXE, 2.1-fold). Delipidation of fetal
calf serum (LPDS) reduced free cholesterol by about
85% and LDL levels by about 96%, whereas triglyceride
levels remained unchanged (data not shown).
Measurements of HMG CoA reductase activity showed
significantly elevated enzyme activities in PXE fibro-
blasts compared to control cells for each cell culture
setting (Figure 2c; +10% FCS: 1.6-fold; +10% LDPS: 1.5-
fold; −FCS: 2.1-fold). Activity was increased in LDPS or
serum-free media in PXE fibroblasts compared to 10%
FCS (+10% LDPS: PXE, 6.4-fold; −FCS: PXE, 2.1-fold)
and a 7.1-fold induction was also observed in control
fibroblasts grown in LPDS. However, overall enzyme ac-
tivity was lower in siRNA-transfected samples comparedFigure 1 Gene expression analysis of ABCC6. (a) Quantification of ABCC
(n = 4; white) and PXE patients (n = 4; black) grown for 24 h under differen
siRNA-mediated knockdown on ABCC6 gene expression: fibroblasts transfe
ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 2
Expression levels are normalized to reference gene expressions (ACTB, GAPDH
standard error. Control: PXE ratio/siABCC6: siNK ratio: ***p < 0.0001; Contro
ratio: +++p < 0.0001; ++p < 0.003; PXE 10% FCS: 10% LPDS, −FCS ratio/siAto PXE and control fibroblasts (Figure 2b). Here, increas-
ing enzyme activities were also detected in LPDS (siNK,
11.6-fold; siABCC6, 5.7-fold) and serum-free treatment of
siRNA control (4.0-fold) compared to 10% FCS. However,
no alterations were found between siNK and siABCC6
samples, except for cells cultivated in 10% FCS (siABCC6/
siNK ratio: 2.0).Lipoprotein deficiency and serum starvation induce
cholesterol biosynthetic gene expression in human
dermal fibroblasts
In addition to HMGCR, marking the rate-limiting step
in cholesterol biosynthesis, gene expression of farnesyl
diphosphate synthase (FDPS), geranylgeranyl diphosphate
synthase 1 (GGPS1), squalene synthase (FDFT1), lanosterol
synthase (LSS), transmembrane 7 superfamily member 2
(TM7SF2) and 7-dehydrocholesterol reductase (DHCR7)
were analyzed (Figures 3 and 4).
Under serum-free conditions, PXE fibroblasts exhib-
ited a significant increase in all targets mentioned above
(except GGPS1) compared to healthy controls, which
were mostly confirmed by ABCC6 knockdown (Figures 3
and 4; FDPS: PXE, 2.0-fold; siABCC6, 1.4-fold; FDFT1:
PXE, 1.8-fold; siABCC6: 1.5-fold; LSS: PXE, 1.5-fold;
siABCC6: 1.5-fold; TM7SF2: PXE, 2.1-fold; siABCC6,
1.8-fold; DHCR7: PXE, 1.6-fold; siABCC6, 1.4-fold; p values
are given in Figures 3 and 4).
Using LPDS, transcript levels of the analyzed targets in
PXE cells were slightly elevated or unchanged relative to
healthy controls (Figures 3 and 4; FDPS: PXE, 1.4-fold;
FDFT1: PXE, 1.1-fold; LSS: PXE, 1.2-fold; TM7SF2: PXE,
1.3-fold; DHCR7: PXE, 1.1-fold; p-values are given in
Figure 3.18, 3.19). ABCC6-silenced fibroblasts showed
even slightly increased or unaltered mRNA levels under6 mRNA expression in human dermal fibroblasts from healthy controls
t cell culture conditions (+10% FCS, +10% LPDS, −FCS). (b) Effect of
cted with a scramble siRNA-negative control (siNK, n = 4; white-striped);
4 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS).
, β2M). Data are presented in arbitrary units as means with corresponding
l 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS
BCC6 10% FCS: 10% LPDS, −FCS ratio: ###p < 0.0001; #p < 0.04.
Figure 2 Gene expression and enzyme activity analysis of HMG CoA reductase (HMGCR). (a) Quantification of HMGCR mRNA expression in
human dermal fibroblasts from healthy controls (n = 4; white) and PXE patients (n = 4; black) grown for 24 h under different cell culture
conditions (+10% FCS, +10% LPDS, −FCS). (b) Effect of siRNA-mediated knockdown on ABCC6 gene expression: fibroblasts transfected with a
scramble siRNA-negative control (siNK, n = 4; white-striped); ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h
under different cell culture conditions (+10% FCS, +10% LPDS, −FCS). Expression levels are normalized to reference gene expressions (ACTB, GAPDH,
β2M). Data are presented in arbitrary units as means with corresponding standard error. Control: PXE ratio/siABCC6: siNK ratio: ***p < 0.0001; *p < 0.03;
Control 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +++p < 0.0001; ++p < 0.004; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6
10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0001 (c, d) Enzyme activity of HMG CoA reductase in fibroblasts of healthy controls, PXE patients (c) and
siRNA- treated cells (d)measured by UPLC-MS/MS. Data are presented in arbitrary units as means with corresponding standard error. Control: PXE
ratio/siABCC6: siNK ratio: **p < 0.003; *p < 0.03; Control 10% FCS: 10% LPDS, -FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +++p < 0.0001; ++p < 0.002;
PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10% LPDS, −FCS ratio: ###p < 0.0001; ##p < 0.009.
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(Figures 3 and 4).
Cell cultivation in 10% LPDS increased mRNA ex-
pression of all targets in PXE and control fibroblasts, as
well as in siRNA treated cells in comparison to 10%
FCS (Figures 3 and 4). Only a slight increase under
serum-free culture conditions was found for gene ex-
pression analysis of GGPS1 in patients and controls
(Figure 3c, d).
Additionally, transcript levels (except FDPS mRNA
expression of control fibroblasts) increased significantly
under serum deprivation (-FCS) compared to standard
cultivation in 10% FCS.
Sterol regulatory element-binding protein 2 (SREBP2) and
sterol regulatory element-binding factor 1 (SREBF1)
increased in response to lipoprotein reduction and serum
withdrawal
Sterol regulatory element-binding protein 2 (SREBP2)
increases LDLR and PCSK9 gene expression, as a sterolsensitive regulator in cholesterol homeostasis [35]. In-
duction of SREBP2 and SREBF1 mRNA expression was
observed in 10% LPDS and serum-free media compared to
10% FCS (Figure 5a-d). No significant changes of SREBP2
transcript levels were detected between PXE and control
cells (Figure 5a). However, SREBF1 mRNA was signifi-
cantly elevated in PXE fibroblasts under serum starvation
(patient/control ratio: 1.5).
Altered gene and protein expression of proprotein
convertase subtilisin/kexin type 9 (PCSK9) and low
density lipoprotein receptor (LDLR) in PXE fibroblasts
Gene expression analysis of PCSK9 by RT2 Profiler PCR
Array revealed a 46-fold increase in PXE fibroblasts
compared to healthy controls grown under serum-free
conditions (see section RT2 Profiler PCR Array).
Verification by further qPCR showed significantly ele-
vated mRNA expression in PXE fibroblasts for all cell cul-
ture settings in comparison to controls (Figure 6a: +10%
FCS: 2.0-fold; +10% LDPS: 2.2-fold; −FCS: 4.1-fold).
Figure 3 Gene expression analysis of cholesterol biosynthesis I: FDPS, GGPS1 and FDFT1. Quantification of (a, b) Farnesyl diphosphate
synthase (FDPS), (c, d) Geranylgeranyl diphosphate synthase (GGPS1) and (e, f) Squalene synthase (FDFT1) mRNA expression in human dermal
fibroblasts from healthy controls (n = 4; white), PXE patients (n = 4; black), scramble siRNA-negative control (siNK, n = 4; white-striped) and
ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS).
Expression levels are normalized to reference gene expressions (ACTB, GAPDH, β2M). Data are presented in arbitrary units as means with corresponding
standard error. Control: PXE ratio/siABCC6: siNK ratio: ***p < 0.0003; **p < 0.003; *p < 0.04; Control 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10%
LPDS, −FCS ratio: +++p< 0.0006; ++p < 0.003; +p < 0.05; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0007.
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lipoprotein-deficient and serum-free conditions in con-
trols and PXE fibroblasts compared to 10% FCS (10%
LPDS: control, 5.1-fold; PXE, 5.5-fold; −FCS: control, 2.4-
fold; PXE, 4.8-fold). Serum-dependent induction of PCSK9
expression was also confirmed in siRNA-transfected fibro-
blasts (Figure 6b), whereas transcript levels of ABCC6-
silenced cells (grown in 10% LPDS) were 2.6-fold higher
than negative controls. Protein expression of PCSK9
was significantly increased in PXE fibroblasts compared
to controls in every cell culture setting (Figure 6c: +10%FCS: 1.7-fold; +10% LDPS: 1.6-fold; −FCS: 1.4-fold).
Protein levels in siRNA treated cells were increased by
trend under LDPS and without FCS. However, no signifi-
cant changes were found between treatments, except for a
slight increase in LPDS according to mRNA expression.
PCSK9 plays a pivotal role in lipoprotein regulation
promoting LDLR degradation [41]. Measurements dis-
played increasing mRNA levels of LDLR under lipopro-
tein deficiency and serum starvation in PXE, control
and siRNA-treated fibroblasts (Figure 6e, f ). Moreover,
gene expression was enhanced in PXE and ABCC6-
Figure 4 Gene expression analysis of cholesterol biosynthesis II: LSS, TM7SF2 and DHCR7. Quantification of (a, b) Lanosterol synthase
(LSS), (c, d) transmembrane 7 superfamily member 2 (TM7SF2) and (e, f) 7-dehydrocholesterol reductase (DHCR7) mRNA expression in human
dermal fibroblasts from healthy controls (n = 4; white), PXE patients (n = 4; black), scramble siRNA-negative control (siNK, n = 4; white-striped) and
ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS).
Expression levels are normalized to reference gene expressions (ACTB, GAPDH, β2M). Data are presented in arbitrary units as means with corresponding
standard error. Control: PXE ratio/siABCC6: siNK ratio: ***p < 0.0005; **p < 0.005; *p < 0.03; Control 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10%
LPDS, −FCS ratio: +++p< 0.0001; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0001; ##p < 0.002.
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controls.
Variations in apolipoprotein gene expression profiles
between PXE fibroblasts and healthy controls
Array analysis indicated differences in gene expression
levels of APOD, APOE and APOL1 between patients’
fibroblasts and controls (see section RT2 Profiler PCR
Array). As shown in Figure 7a, PXE fibroblasts exhib-
ited increased APOD expression compared to controls,
apparently independently of cell culture conditions.However, no differences were found between siRNA-
transfected cells (Figure 5b), whereas mRNA levels
were significantly elevated in serum-free media com-
pared to 10% FCS (siNK, 5.1-fold, p < 0.005; siABCC6,
4.7-fold, p < 0.05).
Strongly depleted gene expression was observed for
APOE in PXE fibroblasts (Table 1) by array analysis.
This was confirmed by further qPCR which revealed
an overall decrease of 93- 94% in APOE transcript levels
in comparison to controls (Figure 7c). Though, no signifi-
cant alterations were detected between ABCC6-silenced
Figure 5 Gene expression analysis of Sterol regulatory element-binding protein 2 (SREBP2) and sterol regulatory element binding
factor 1 (SREBF1). Quantification of (a, b) Sterol regulatory element-binding protein 2 (SREBP2) and (c, d) sterol regulatory element binding
factor 1 (SREBF1) mRNA expression in human dermal fibroblasts from healthy controls (n = 4; white), PXE patients (n = 4; black), scramble
siRNA-negative control (siNK, n = 4; white-striped) and ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h under
different cell culture conditions (+10% FCS, +10% LPDS, −FCS). Expression levels are normalized to reference gene expressions (ACTB, GAPDH,
β2M). Data are presented in arbitrary units as means with corresponding standard error. Control: PXE ratio/siABCC6: siNK ratio: **p < 0.006; Control
10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +++p < 0.0002; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10%
LPDS, -FCS ratio: ###p < 0.0008; #p < 0.03.
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expressions of APOE in 10% FCS and without serum
supplementation (Figure 7d). In general, APOE gene ex-
pression was highly induced under serum starvation in
control fibroblasts (4.3-fold) and siRNA negative controls
(2.5-fold; Figure 7c, d). Measurements of APOE transcript
levels were accompanied by genomic sequence analysis of
APOE allele variations in patients and control samples
(Additional file 4: Table S4). Two PXE patients and con-
trols were found to carry the abundant ε3 isoform homo-
zygously, whereas one PXE patient carried the ε3/ε2
alleles in heterozygous state. Two controls were found to
bear the heterozygous ε3/ε4 genotype. Additionally, the ε2
isoform was detected for PXE patient 1 in homozygous
state.
PXE fibroblasts showed increased APOL1 gene expres-
sion in serum-free media in comparison to controls
(Table 1). These results were confirmed by further RTQ-
PCR measurements, as shown in Figure 7e. APOL1
expression was significantly higher in patients’ cells
compared to controls in 10% FCS (1.9-fold) and -FCS(2.2-fold), whereas cultivation in lipoprotein-deficient
serum showed just a slight increase. However, no signifi-
cant alterations were found between siRNA-treated fibro-
blasts (Figure 7f).
Gene expression of CYP27A1- a marker for cholesterol
hydroxylation and bile acid synthesis
Gene expression of cytochrome P450, family 27, subfamily
A, polypeptide 1 (CYP27A1) was significantly induced in
cells grown in 10% LPDS and without serum supplemen-
tation (Figure 8a, b). PXE fibroblasts were found to exhibit
higher transcript levels under serum starvation in com-
parison to healthy controls (1.7-fold), whereas expression
was slightly decreased in LPDS (20%; Figure 8a). However,
no differences were detected between ABCC6-silenced
fibroblasts and controls (Figure 8b).
Targeting ABCC2 and ABCC3- important members of bile
salt transport
PXE fibroblasts grown in serum-free media showed 2.0-
fold increase in ABCC2 gene expression, compared to
Figure 6 Gene and protein expression analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and low density lipoprotein
receptor (LDLR). Quantification of (a, b) mRNA (c, d) PCSK9 protein content (pg/ ml) and (e, f) LDLR mRNA expression in human dermal
fibroblasts from healthy controls (n = 4; white), PXE patients (n = 4; black), scramble siRNA-negative control (siNK, n = 4; white-striped) and ABCC6-
specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS).
Gene expression levels are normalized to reference gene expressions (ACTB, GAPDH, ß2M). Cell lysates for ELISA analysis were pooled from three
biological replicates, measured in duplicates. Data are presented in arbitrary units as means with corresponding standard error. Control: PXE
ratio/siABCC6: siNK ratio: ***p < 0.0001; **p < 0.003; *p < 0.05; Control 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +++p <
0.0001; ++p < 0.002; +p < 0.02; PXE 10% FCS: 10% LPDS, -FCS ratio/siABCC6 10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0001; #p < 0.03.
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hand, the expression pattern of control fibroblasts and
siRNA-transfected cells was unchanged or moderately
depleted between cell culture settings (Figure 9a, b).
Analysis of ABCC3 mRNA expression revealed sig-
nificant reduction in PXE and ABCC6-silenced cells
compared to controls (Figure 9c, d). A 50- 60% reduc-
tion was found in PXE fibroblasts, whereas ABCC6-
knockdown exhibited 20- 35% depletion. These regulations
were found to be independent of cell culture conditions.Discussion
In this study, we describe for the first time alterations in
cellular cholesterol and lipoprotein metabolism in human
dermal fibroblasts from patients with Pseudoxanthoma
elasticum. Gene expression analysis of 84 targets involved
in cholesterol biosynthesis and lipoprotein assembly in-
dicated dysregulations in response to ABCC6 defi-
ciency. Highly increased or downregulated genes were
further examined under different cell culture conditions
(+10% FCS, +10% LPDS, −FCS), inducing HMG CoA
Figure 7 Gene expression analysis of Apolipoproteins: APOD, APOE and APOL1. Quantification of (a, b) apolipoprotein D (APOD), (c, d)
apolipoprotein E (APOE) and (e, f) apolipoprotein L1 (APOL1) mRNA expression in human dermal fibroblasts from healthy controls (n = 4; white),
PXE patients (n = 4; black), scramble siRNA-negative control (siNK, n = 4; white-striped) and ABCC6-specific siRNA-treated cells (siABCC6, n = 4;
black-shaded) grown for 24 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS). Expression levels are normalized to reference
gene expressions (ACTB, GAPDH, β2M). Data are presented in arbitrary units as means with corresponding standard error. Control: PXE ratio/siABCC6:
siNK ratio: ***p < 0.0001; *p < 0.03; Control 10% FCS: 10% LPDS, -FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +++p < 0.0004; ++p < 0.003; +p < 0.04;
PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0001; ##p < 0.005; #p < 0.05.
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analysis could not be confirmed by additional qPCR,
pointing towards the need for additional data verifica-
tion of microarray analysis by secondary methods [42].
Transcript levels of ABCC6 were strongly increased in
lipoprotein-deficient serum (LPDS) and under serum-free
conditions in control and siRNA treated cells. ABCC6 si-
lencing reached 65- 75%, whereas mRNA expression levels
of ABCC6 were overall diminished in siRNA treatments
in comparison to controls without transfection. To what
extent this was caused by liposome-based transfection, or
enlarged cultivation time (+24 h) for siRNA treatments isnot clear. As shown before, no ABCC6 mRNA could be
detected in fibroblasts from PXE patients [18].
The main results of this study are summarized in
Figure 10. We used human dermal fibroblasts as a cellular
model for ABCC6 deficiency in peripheral cells, in
addition to their functional role in extracellular matrix as-
sembly. Previously published data showed that fibroblasts
from PXE patients exhibit a characteristic phenotype
distinct from healthy controls, affecting ABC transporter
expression [18], calcification processes [43], or extracellu-
lar matrix organization [44,45]. ABCC6 is predominately
expressed in the liver and kidney and transcript levels in
Figure 8 Gene expression analysis of CYP27A1. Quantification of (a, b) CYP27A1a mRNA expression in human dermal fibroblasts from healthy
controls (n = 4; white), PXE patients (n = 4; black), scramble siRNA-negative control (siNK, n = 4; white-striped) and ABCC6-specific siRNA-treated
cells (siABCC6, n = 4; black-shaded) grown for 24 h under different cell culture conditions (+10% FCS, +10% LPDS, −FCS). Expression levels are
normalized to reference gene expressions (ACTB, GAPDH, β2M). Data are presented in arbitrary units as means with corresponding standard error.
Control: PXE ratio/siABCC6: siNK ratio: **p < 0.002; *p < 0.05; Control 10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio:
+++p < 0.0002; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10% LPDS, -FCS ratio: ###p < 0.0001; #p < 0.04.
Figure 9 Gene expression analysis of ABCC-Transporters ABCC2 and ABCC3. Quantification of (a, b) ABCC2 and (c, d) ABCC3 mRNA
expression in human dermal fibroblasts from healthy controls (n = 4; white), PXE patients (n = 4; black), scramble siRNA-negative control (siNK,
n = 4; white-striped) and ABCC6-specific siRNA-treated cells (siABCC6, n = 4; black-shaded) grown for 24 h under different cell culture conditions
(+10% FCS, +10% LPDS, −FCS). Expression levels are normalized to reference gene expressions (ACTB, GAPDH, β2M). Data are presented in
arbitrary units as means with corresponding standard error. Control: PXE ratio/siABCC6: siNK ratio: ***p < 0.0002; **p < 0.005; *p < 0.02; Control
10% FCS: 10% LPDS, −FCS ratio/siNK 10% FCS: 10% LPDS, −FCS ratio: +p < 0.03; PXE 10% FCS: 10% LPDS, −FCS ratio/siABCC6 10% FCS: 10%
LPDS, -FCS ratio: ###p < 0.0009; ##p < 0.005.
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Figure 10 Proposed molecular mechanisms underlying the dysregulations in cholesterol and lipoprotein metabolism in ABCC6-deficient
PXE fibroblasts. In case of ABCC6-deficiency in the liver, the potential substrate(s) of ABCC6 is/are missing in the circulation (1). Hepatocytes might
possess substitutional routes to prevent possible toxic substrate accumulations (e.g. biliary excretion by other ABC transporter/s). Insufficient substrate
supply by the liver then induces substrate biosynthesis in ABCC6-deficient dermal fibroblasts (e.g. cholesterol biosynthesis) (2). Due to a functional loss
of ABCC6, newly synthesized metabolites accumulate intracellularly (3) and might provide an additional trigger for dysregulations in cholesterol
homeostasis in addition to insufficient hepatic substrate supply.
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pathogenesis of PXE is currently explained by the “meta-
bolic hypothesis” and the “peripheral cell hypothesis”
[46,47]. In case of ABCC6 deficiency in the liver, potential
substrate(s) of ABCC6 is/are missing in the circulation,
which leads to the ectopic mineralization processes in per-
ipheral tissues. However, the liver is not affected in PXE
patients and hepatocytes might possess substitutional
routes to prevent possible toxic substrate accumulations
(e.g. biliary excretion by other ABC transporter/s). Theor-
etically, mineralization can occur due to substrate defi-
ciency in peripheral tissues, which normally counteracts
calcification processes. On the other hand, mineralization
can be forced by intracellular substrate biosynthesis in
ABCC6-deficient cells (e.g. dermal fibroblasts), which is
induced by insufficient substrate supply by the liver and
subsequent harmful accumulation affecting intracellular
pathways. Recent studies have demonstrated that choles-
terol and its precursors are mainly generated in the liver
(supplying extrahepatic tissues) [48,49], but can even be
newly synthesized by peripheral cells, e.g. by human der-
mal fibroblasts [50,51].Many ABC transporters are involved in lipid homeo-
stasis, including RCT and phospholipid or cholesterol ef-
flux [3,26]. Recent studies showed variations in plasma
and serum lipoprotein and triglyceride concentrations in
PXE patients [27,29]. We investigated human dermal fi-
broblasts from PXE patients and healthy controls under
standard cell culture conditions and by inducing choles-
terol biosynthesis (HMGCR activity) through lipoprotein
deficiency (LPDS) or serum-free (−FCS) cultivation, as
shown before [36,50]. Measurement of HMG CoA reduc-
tase activity showed for the first time a significant increase
in cholesterol biosynthesis rates in PXE fibroblasts in com-
parison to healthy controls, which was observed under all
tested cell culture settings. These data were confirmed
by further qPCR measurements of important targets in
cholesterol biosynthesis (FDPS, GGPS1, FDFT1, LSS,
TM7SF2, DHCR7), which revealed overall increased tran-
script levels in PXE patients, predominately under serum
starvation and using LPDS. Therefore, our data indicate a
conceivable role for ABCC6 in human cellular cholesterol
and lipoprotein metabolism, observing significant dif-
ferences between PXE fibroblasts and healthy controls.
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the molecular mechanisms underlying the positive out-
come of statin treatment observed in Abcc6−/− mice
[31,52]. Moreover, newly published data including whole-
genome sequencing of 89 individuals of polar and brown
bears revealed that ABCC6 is one of the important genes
which has been under high positive selection in polar
bears, enabling to deal with life-long elevated LDL levels
that are associated with high risk of heart disease in
humans [53].
Most of these results were approved by siRNA knock-
down experiments. However, highest ABCC6 mRNA
expression under serum starvation could not directly
be correlated to the highest HMGCR activity, which
was found in 10% LPDS. Nevertheless, higher choles-
terol biosynthesis in PXE could be an important pro-
atherosclerotic factor also affecting calcification progress.
The missing correlation of HMG CoA activity and ABCC6
mRNA levels could be explained by further serum factors
which may participate in transcription control or act as
direct substrate/s for ABCC6. Therefore, cell cultivation
in LPDS and without FCS could underlie different regu-
lations, while substrate/s of ABCC6 could be still existent
in LPDS.
Gene expression array data indicated strongly increased
transcript levels for the proprotein convertase subtilisin/
kexin type 9 (PCSK9) in PXE fibroblasts, which was also
confirmed by additional qPCR and ELISA measurements.
Gene expression levels of the LDLR were slightly elevated
in PXE fibroblasts and ABCC6-silenced cells compared
to controls.
Our study is the first linking ABCC6 deficiency to in-
creased PCSK9 mRNA and protein levels. Pisciotta et al.
examined a hypercholesterolemic PXE patient, who
was compound-heterozygous for two ABCC6 mutations
(p.S317R and p.R1141X) and for further mutations in can-
didate genes causing autosomal co-dominant hypercholes-
terolemia [54]. A heterozygous LDLR mutation (p.R574H)
was found in this patient, whereas no sequence variations
were identified in the PCSK9 gene. PCSK9 is mainly
expressed in the liver, but was also found in human fibro-
blasts [55] (similar to the expression pattern of ABCC6)
and plays an important role in LDL receptor lysosomal
degradation [41]. Modification of serum lipoprotein con-
tent, as well as serum withdrawal, induced PCSK9 gene
and protein expression in our experiments. PCSK9 was
shown to be increased by peroxisome proliferator-
activated receptor gamma (PPARγ) ligands [56], bisphos-
phonate administration [57], statin use or by LXR-agonists
[58,59]. On the other hand, farnesoid X Receptor (FXR)
agonists, 24(S), 25-epoxycholesterol and the lanosterol
synthase inhibitor OSCi decreased PCSK9 expression in
human hepatocytes and vascular smooth muscle cells,
respectively [58,59]. Interestingly, induction of PCSK9expression by PPARγ ligands was supposed to be
dependent on extracellular signal regulated kinases 1 and
2 (ERK 1/2) inhibition [56]. The ERK1/2- hepatocyte nu-
clear factor 4 alpha (HNF4α)-axis has been previously de-
scribed as an important factor for ABCC6 transcription
control and might be an additional link to the observed el-
evated PCSK9 levels in PXE fibroblasts [60]. In addition to
increased cholesterol biosynthesis found in PXE fibro-
blasts, elevated PCSK9 levels could force atherogenesis
and cardiovascular risk in PXE patients. Thus, known reg-
ulators for PCSK9 (e.g. oxysterols, bile acids) should be in-
vestigated as potential substrate/s for ABCC6 in future
studies.
Decreased levels of apolipoprotein E (APOE) are an
additional risk factor for the development of atheroscler-
osis. APOE plays an important role in chylomicron and
very low density lipoprotein (VLDL) recycling, interacting
with LDL receptors in the liver [61]. Single nucleotide
variants in APOE were described as determinants for
receptor interaction rates and risk factors for athero-
sclerosis, hypercholesterolemia or Alzheimer disease
[62]. We found different APOE isoforms, like heterozy-
gous ε3/ε2 and homozygous ε2 alleles in PXE patients
and heterozygous ε3/ε4 in controls, in addition to the
abundant homozygous ε3 isoform. The presence of at
least one ε2 allele was associated with higher APOE
levels and a lower risk for CHD, whereas at least one al-
lele of the isoform ε4 was shown to predict lower
APOE levels and a higher potential to develop CHD
and Alzheimer disease [62]. One PXE patient was even
characterized by a homozygous ε2 isoform of APOE,
which can be a risk factor for type III hyperlipoprotei-
nemia in 5- 10% of ε2 homozygous carriers [62].
Gene expression data of array analysis displayed a strong
reduction in APOE transcript levels in PXE fibroblasts.
We confirmed our observations by further qPCR, whereby
mRNA expression of APOE exhibited a significant in-
crease in LPDS and under serum-free cell culture condi-
tions, comparable to the ABCC6 expression pattern.
Genetic variations in APOE isoforms between examined
subjects were considered by an additional analysis of
homozygous ε3 carriers (PXE 1/2 and Ctl 2/3; data not
shown). Comparison of APOE transcript levels of these
samples revealed as well significantly reduced levels in
PXE patients in 10% FCS (0.25-fold) and under serum
starvation (0.15-fold). Hence, mRNA expression seemed
to be regulated independently of genetic polymorphisms
of APOE in patients and controls, as recently shown in
mononuclear cells from normolipidemic and hypercho-
lesterolemic individuals [63]. For ABCC6-silenced cells,
only a slight decrease in APOE mRNA (in 10% FCS and
without FCS) was detected in comparison to scrambled
siRNA negative controls. However, these differences
could be due to residual ABCC6 protein content of
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carried out with liposomes, which might have a still un-
known impact on overall lipoprotein metabolism.
Increased APOE levels in fibroblasts have recently
been described under serum starvation [64]. Furthermore,
Ishibashi et al. observed increased PCSK9 expression and
decreased hepatic LDLR levels in Apoe −/− and Niemann-
Pick type C1 (Npc1-/-) double knock-out mice [65]. These
data suggest dependent regulations between APOE and
PCSK9, which might also be important for molecular
pathomechanisms in PXE. However, in addition to its
functional role in lipoprotein metabolism, regulatory
properties in the extracellular matrix and intracellular
calcium homeostasis were also described for APOE
[66]. Measurement of mRNA expression for APOD and
APOL1 also showed significantly increased levels in
PXE fibroblasts in comparison to controls, mainly under
serum-free conditions. Interestingly, APOD expression
was described as increasing under oxidative stress as a
protective cellular response [67,68], a characteristic
cellular hallmark in PXE [69].
In addition to these new observations in cholesterol
biosynthesis and lipoprotein metabolism in PXE fibro-
blasts, we found increased transcript levels of CYP27A1 in
PXE fibroblasts under serum starvation. However, mRNA
expression data were not confirmed by siRNA-mediated
knockdown. CYP27A1 is a member of the cholesterol-
hydroxylating enzymes (forming 27-hydroxycholesterol/
27-OH) expressed in most body tissues, whereas circulat-
ing 27-OH is further converted into bile acids in the liver
[70]. Increasing expression of CYP27A1 could be a cellular
response to higher cholesterol biosynthesis rates [71], as
shown here for PXE fibroblasts. However, elevated levels
of side-chain hydroxylated oxysterols (27-OH) would be
expected to inhibit newly synthesized cholesterol reversely,
acting as a LXR ligand [70].
Cellular lipoprotein and cholesterol homeostasis is
regulated by intra- and extracellular processes, including
the sterol regulatory element-binding proteins (SREBPs) as
essential members of transcription control [72]. SREBP2
orchestrates the induction of LDLR, PCSK9 and HMGCR
in response to sterol depletion [56]. Gene expression ana-
lysis of SREBP2 showed a comparable increase under
LPDS and serum-free conditions for controls and PXE fi-
broblasts, as well as for siRNA-transfected cells. Transcript
levels of SREBF1 were increased in 10% LPDS, but were
even higher in serum-free media. SREBF1 can be induced
by insulin or liver X receptor (LXR) agonists [73,74] and
was shown to be significantly elevated in PXE fibroblasts
under serum deprivation in comparison to controls.
Induction of ABCC2 transcription was recently shown
in PXE fibroblasts [18]. These ABC transporters are
closely related to ABCC6 [75]. ABCC2 was shown to
increase significantly under serum deprivation in PXEfibroblasts. Interestingly, reduction in ABCC3 mRNA
levels in PXE fibroblasts and ABCC6-silenced cells,
seem to be absolutely independent of cholesterol bio-
synthesis, or lipoprotein supply. Recently, Kobayashi
et al. found that gene regulation of ABCC2 is linked to
LXR-SREBP regulatory pathways [76]. These connection
should also be investigated for ABCC6, using promotor
analysis for the detection of possible transcriptional factor
binding sites for SREBPs.
This is the first study which links ABCC6 deficiency to
higher cholesterol biosynthetic rates, alterations in LDLR-
PCSK9 regulation and decreased APOE mRNA expres-
sion. All findings are important atherosclerotic risk factors
and should be investigated in future studies, exploring the
functional role of ABCC6 in the pathogenesis of PXE and
related diseases.
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